Literature DB >> 25219125

[Effect of electroacupuncture stimulation of "Feishu" (BL 13) on lung index, serum and lung IL-10 and TNF-alpha levels in mice with viral pneumonia].

Wei Luo, Jun-Ying Wang, Chun-Lei Liu, Chao Huang.   

Abstract

OBJECTIVE: To observe the effect of electroacupuncture (EA) stimulation of "Feishu" (BL13) on lung pathological changes, and levels of pulmonary and serum IL-10 and tumor necrosis factor (TNF)-alpha in viral pneumonia mice, so as to explore its mechanisms underlying improvement of viral pneumonia.
METHODS: Fifty Kunming mice were randomly divided into normal control, model, medication, EA and moxibustion groups, with 10 mice in each group. The viral pneumonia model was established by intra-nose drip of influenza A1 virus FM1 (H1N1). Rats of the EA group were treated by EA stimulation of bilateral BL13, those of the moxibustion group treated by ignited moxa-stick, and those of the medication group treated by intraperitoneal injection of Yanhuning injection (10 mg x Kg(-1) x d(-1), solved in 5% glucose solution, 5 mL/time/mouse, once daily for 1 week). Both EA and moxibustion treatments were conducted for 20 min, twice a day for a week. The lung index [lung weight/body weight x 100%] were calculated after the treatment. Pathological changes of the lung were observed under microscope after H.E. staining, and serum and pulmonary IL-10, TNF-alpha levels were detected using solid phase sandwich enzyme-linked immunosorbent assay.
RESULTS: Following modeling, the average lung index, serum TNF-alpha, and pulmonary TNF-alpha and IL-10 levels were significantly increased in the model group (P < 0.05), while after the treatment, the average lung index and serum TNF-alpha and pulmonary IL-10 levels in the EA, moxibustion and medication groups were notably down-regulated (P < 0.05, P < 0.01), and serum IL-10 contents of the three treatment groups were obviously up-regulated (P < 0.01). The effect of the EA group was apparently superior to that of the medication group in down-regulating lung index (P < 0.05). No significant differences were found among the three treatment groups in the levels of serum TNF-alpha and IL-10, and pulmonary TNF-alpha and IL-10 (P > 0.05). In addition, results of H. E. stain showed that the treatment of medication, moxibustion and EA might reduce H1N1-induced pulmonary pathological changes.
CONCLUSION: EA stimulation of "Feishu" (BL13) can down-regulate lung index and serum TNF-alpha and up-regulate serum IL-10 level in viral pneumonia mice, which may contribute to its effect in relieving asthma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25219125

Source DB:  PubMed          Journal:  Zhen Ci Yan Jiu        ISSN: 1000-0607


  4 in total

1.  Effect of Transcutaneous Electrical Acupoint Stimulation on One-Lung Ventilation-Induced Lung Injury in Patients Undergoing Esophageal Cancer Operation.

Authors:  Fangchao Zhao; Zengying Wang; Chengyuan Ye; Jianming Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-07       Impact factor: 2.629

2.  Examining the Effector Mechanisms of the Feishu Acupoint (BL13) in the Treatment of Pneumonia Based on Systematic Acupuncture and Moxibustion Research.

Authors:  Yan Xu; Jiali Cai; Weibin Li; Jingkun Miao; Yan Mei; Xinna Wang; Hanying Xu; Qixiong Chen; Fang Liu; Hongtao Cui
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-05       Impact factor: 2.629

3.  Transcutaneous Electrical Acupoint Stimulation Improves Immunological Function During the Perioperative Period in Patients With Non-Small Cell Lung Cancer Undergoing Video-Assisted Thoracic Surgical Lobectomy.

Authors:  Qing Tu; Zhou Yang; Jianhui Gan; Jian Zhang; Bin Que; Qiaofeng Song; Yan Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 4.  Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.

Authors:  Shengyan Xi; Yunhong Li; Lifeng Yue; Yuewen Gong; Linchao Qian; Tengxiao Liang; Yong'an Ye
Journal:  Front Pharmacol       Date:  2020-10-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.